Metafora biosystems, a Paris, France-based company developing diagnostic tests to detect abnormalities in cellular energetics, received a European grant of €3.2m ($3.75M).
The grant was part of the phase 2 of the European Commission’s H2020 SME Instrument program.
The company intends to use the funds to accelerate its clinical and regulatory development processes.
Led by Vincent Petit, CEO, Metafora is launching a large-scale prospective validation study of METAglut1, its test to help early diagnosis of De Vivo disease (Glut1 deficiency syndrome). It has already obtained the necessary authorizations for this study from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Committee for the Protection of Persons (CPP). The study will be carried out in collaboration with more than 40 neurology centers in France, including the Pitié Salpêtrière and Robert Debré (AP-HP) hospitals, and Laboratoire Cerba. It will last until 2020, with the results expected to be published early 2021.
Metafora also plans to start regulatory proceedings in various European countries and in the United States with the objective of marketing its diagnostic test more widely. The European grant will also help with international expansion.